65 New Third Board IVD Companies, Sales, Profit Analysis

Pharmaceutical News May 17th At present, the 2017 annual report of Xinsanban companies has basically been completed.

As of April 30, a total of 11,382 companies were listed on the New Third Board. The main business is medicine Biologically related enterprise There are 654 companies, of which 65 are in vitro diagnostic companies. According to the 65 annual reports disclosed in 2017, related sales, profit analysis is as follows:

The 65 in-vitro diagnostic companies that have disclosed the 2017 annual report have a total revenue of 4.390 billion yuan, with an average operating income of 67.349 million yuan, a year-on-year increase of 33.14%. Of these, 14 companies have a revenue of over 100 million yuan, and 5 companies have a 100% year-on-year increase in operating revenues. .

Total 65 net profit of 65 in-vitro diagnostic companies were attributable to their mothers, total net profit was 325 million yuan, and the average net profit attributable to their mothers was 499.54 million yuan, an increase of 35.73% over the same period of last year. The average net interest rate was 7.40%. Of these, 11 companies had net profits of over 20 million yuan, and 6 companies Net income of mothers increased by 200% year-on-year.

We compared the in-vitro diagnostic companies of Xinsanban with 22 mainboard in-vitro diagnostic companies including Daan Gene, Antu Biology, and Kehua Biology. In terms of scale, the operating income and net profits of new Sanban companies Both are significantly smaller than those of the main board companies; however, in terms of the growth rate, the operating income of the new three boards and the net profit of their home owners are basically the same as those of the main board companies in 2016.

After analyzing the performance of the in-vitro diagnostics companies in 2017, we found that the revenue growth rate of the five biochemical diagnostic companies was the fastest, reaching 59.52%, far higher than the average annual growth rate of 7% in the biochemical diagnostics industry in China, and the growth rate of net profit. only 24.54 percent, indicating a higher degree of concentration of biochemical diagnostic industry, domestic alternative speeds up, but the fierce competition in the industry, cost pressures, gross margin decreased resulting in lower profit margins.

Similarly, in the field of POCT, net profit growth of the parent group reached 78.25%, which is the fastest growing subdivided area. Its growth rate is also much higher than the average annual growth rate of China's POCT industry by 20%, indicating that the POCT industry is highly concentrated.

Among the in-vitro diagnostic companies of the New Third Board, 21 companies in the field of molecular diagnostics performed the most dazzlingly, operating income increased by 52.86%, and net profit at home was 514.45%, indicating the concept of 'precise treatment' with 'precision diagnosis'. Gradually deep in people's hearts, huge demand will drive the rapid growth of the molecular diagnostics industry.

The revenue growth rate of the five new POCT companies in the New Third Board was relatively fast, reaching 39.50%. However, the growth rate of net profit was not satisfactory at only 7.00%, which was much lower than that of the domestic POCT industry. This may be due to the domestic POCT sector. Industry competition began to increase, resulting in a drop in gross margins.

The operating income of nine immunodiagnostic enterprises in Xinsanban increased by 18.61% year-on-year, but the net profit attributable to the mothers fell by 99.80%, which is inconsistent with the average annual growth rate of 20% in the immunodiagnostic industry in China. Immunity (ELISA) products, these products have gradually been replaced by the rapid development of chemiluminescence products, resulting in pressure on the new three board immune diagnostic companies to increase prices, profitability space is compressed.

From May 2017 to May 2018, a total of 8 companies have successively delisted, among which there are many leading companies in each segment, such as New Industry, Mingde Biology, Feipeng Bio, etc. Some companies have successfully landed A shares after delisting. .

From the perspective of the overall performance, the average revenue and net profit of the eight delisted companies during the latest reporting period were 291 million and 82.72 million, respectively, which were much higher than the overall level of the in vitro diagnostics board. This proves that the new three boards have been successfully incubated. A group of high-quality in vitro diagnostic companies, at the same time, the delisting of these companies also led to a certain degree of decline in the overall scale of the new in vitro diagnostic plate.